Shobhit Baijal, MBBS, MRCP, MRCP, The University Hospital Birmingham NHS Trust, Birmingham, UK, discusses recent advances in the lung cancer treatment landscape including capmatinib, which targets MET exon 14 skipping (METex14) mutations in lung cancer. The accelerated approval process devised by regulatory authorities has enabled more drugs to be used in the clinic and Dr Baijal additionally highlights novel checkpoint inhibitors that may be approved in the UK. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.